An online graded backflushing system and its control method, as well as a dual plasma filtration system incorporating the same.
The online graded backflushing system enables independent reverse transmembrane flushing of the primary and secondary membranes in the dual plasma filtration system, solving the membrane clogging problem, extending filter life, reducing consumable costs, and improving treatment safety.
Patent Information
- Application Number
- CN202611427779.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-15
- Publication Date
- 2026-11-17
AI Technical Summary
In existing dual plasma filtration systems, membrane surface protein deposition causes severe blockage, lacks active maintenance mechanisms, cannot perform differentiated maintenance, is only equipped with forward flushing, and flushing control relies on manual experience. Improper treatment of backflushing waste liquid can easily lead to safety risks, and the cost of consumables is high.
The design includes an online graded backflushing system, comprising a backflushing fluid source, independent first and second backflushing branches, flow control components, pressure monitoring components, and a control unit. The system independently triggers reverse transmembrane flushing through real-time transmembrane pressure monitoring, enabling differentiated maintenance of the primary and secondary membranes.
It significantly improves the unblocking effect, extends the filter's service life, reduces consumable costs, enhances treatment safety, and reduces the amount of backflushing fluid used. It is suitable for volume-sensitive individuals such as those with heart failure or liver failure.
Smart Images

Figure CN123102157A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of medical device technology, and in particular to an online graded backflushing system and its control method, as well as a dual plasma filtration system comprising the same. Background Technology
[0002] Dual plasma filtration (DFPP) is a selective plasma purification technology that achieves stratified purification through two stages of hollow fiber membranes: a primary plasma separator (large pore size) separates blood cells from plasma, while a secondary plasma component separator (small pore size) retains large-molecule pathogenic substances in the plasma (such as immune complexes, low-density lipoprotein, IgM, fibrinogen, etc.), while retaining small-molecule beneficial substances such as albumin for reinfusion into the body. This technology is widely used in the treatment of autoimmune diseases, hyperlipidemia, severe pancreatitis, and other diseases.
[0003] like Figure 1 As shown, in existing DFPP equipment and systems, the primary plasma separator and the secondary plasma component separator are arranged in series along the blood / plasma flow direction. During treatment, the transmembrane pressure of both stages needs to be maintained within the normal range to ensure purification efficiency. However, the existing technology has the following core technical defects: (i) Membrane surface is severely blocked by protein deposition, and the existing system lacks an active maintenance mechanism. Secondary plasma component separators have extremely small pore sizes (typically 0.01~0.04μm). During treatment, large molecules such as lipoproteins, immunoglobulins, and fibrinogen are rapidly adsorbed onto the inner membrane wall, forming a dense protein deposit layer, causing a sharp increase in transmembrane pressure (TMP) within a short period. In existing DFPP systems, both the primary and secondary separators operate passively, only being manually replaced by operators when the filters become unusable due to clogging. This lack of real-time monitoring and proactive intervention mechanisms for membrane clogging often forces the replacement of the entire filter system mid-treatment due to secondary membrane clogging, resulting in treatment interruptions and high consumable costs.
[0004] (ii) Lack of a graded and independent flushing structure, making differentiated maintenance impossible. The membrane pore sizes of primary and secondary plasma separators differ significantly (primary pore size is typically 0.2–0.5 μm, while secondary pore size is only 0.01–0.04 μm). Their clogging rates and mechanisms during treatment are completely different—primary membranes primarily face blood cell adhesion, while secondary membranes face dense deposition of lipoproteins and immune complexes. However, in existing DFPP systems, the two filters are connected in series via tubing, sharing the same plasma flow path. There is a lack of independent backflushing pathways and flow control structures specifically designed for each membrane stage, making differentiated maintenance impossible. This results in either excessive flushing of the primary membrane, wasting fluid, or insufficient flushing of the secondary membrane, leading to premature failure.
[0005] (iii) The forward flushing system alone is insufficient to effectively remove firmly deposited sediments. Existing DFPP systems are only equipped with saline forward flushing tubing and corresponding on / off control structures. The flushing fluid flows forward along the blood side through the hollow fiber lumen, which can only flush away free plasma impurities and cannot remove protein deposits that have firmly adhered to the membrane wall, resulting in a weak effect on restoring membrane permeability. More importantly, the existing tubing structure lacks a pathway design for reverse flushing fluid delivery from the outside of the membrane to the inside, making it impossible to achieve reverse physical removal of deposits from the membrane wall.
[0006] (iv) The flushing control relies on human experience and lacks a precise triggering and independent adjustment mechanism. In clinical practice, the timing, duration, and flow rate of existing DFPP systems all rely on the operator's subjective judgment and experience, lacking an automatic triggering mechanism based on real-time transmembrane pressure monitoring data. Furthermore, because the two membrane stages share the same flushing path, it is impossible to adjust the flushing pressure, flow rate, and duration separately, making it difficult to achieve precise backflushing control tailored to different levels of clogging in the two membrane stages.
[0007] (v) Improper treatment of backflushing waste liquid can easily lead to safety risks. If backflushing is simply modified on existing equipment, the detached protein clots and microthrombi could be reinfused into the patient with the backflushing fluid, posing a serious risk of embolism. Current technology lacks a supporting structure for the safe collection or filtration of backflushing waste fluid from both membrane stages.
[0008] In summary, existing DFPP systems lack a graded independent reverse flushing structure based on real-time transmembrane pressure monitoring for the two-stage filters. This makes it impossible to perform independent and controllable reverse transmembrane flushing of the primary and secondary membranes during treatment, in order to delay membrane clogging and extend filter lifespan.
[0009] The above background information is provided only to aid in understanding the concept and technical solution of this invention. It does not necessarily belong to the prior art of this patent application. In the absence of clear evidence that the above information was disclosed on the filing date of this patent application, the above background information should not be used to evaluate the novelty and inventiveness of this application. Summary of the Invention
[0010] The purpose of this invention is to provide an online graded backflushing system and its control method, as well as a dual plasma filtration system including the same, to solve the problems existing in the prior art, so that reverse transmembrane flushing can be independently triggered according to the real-time status of the two membranes during treatment, effectively delaying membrane clogging, extending filter life and reducing consumable costs.
[0011] To achieve the above objectives, the present invention provides the following solution: An online graded backflushing system, applied to a dual plasma filtration device, is characterized by comprising: Backflush fluid source, used to provide backflush fluid; The first backflush branch is used to connect the backflush liquid source to the membrane external interface of the primary plasma separator, and a first flow control element is provided on the first backflush branch. The second backflush branch is used to connect the backflush liquid source to the membrane external interface of the secondary plasma component separator. A second flow control element is provided on the second backflush branch. A first pressure monitoring device is used to monitor the transmembrane pressure of the primary plasma separator; A second pressure monitoring device is used to monitor the transmembrane pressure of the secondary plasma component separator; The control unit is electrically connected to the first flow control element, the second flow control element, the first pressure monitoring element, and the second pressure monitoring element, respectively. The control unit independently controls the on / off state of the first backflushing branch and the second backflushing branch and the backflushing parameters according to the monitoring values of the first pressure monitoring element and the second pressure monitoring element, so as to perform independent reverse transmembrane flushing on the primary plasma separator and the secondary plasma component separator, respectively.
[0012] In an exemplary embodiment, the control unit incorporates a tiered backflush control algorithm. When the monitored value of the first pressure monitoring device reaches a preset first-stage membrane backflush trigger threshold, the control unit triggers a first-stage membrane backflush procedure, controlling the first flow control device to open the first backflush branch. When the monitored value of the second pressure monitoring device reaches a preset second-stage membrane backflush trigger threshold, the control unit triggers a second-stage membrane backflush procedure, controlling the second flow control device to open the second backflush branch. The first-stage membrane backflush procedure and the second-stage membrane backflush procedure are independent of each other and can be executed in a time-sharing manner.
[0013] In one exemplary embodiment, the first pressure monitoring element is connected via a first pressure monitoring tube to the pipeline between the membrane outer interface of the primary plasma separator and the first flow control element. The first pressure monitoring tube contains gas, and the first pressure monitoring element characterizes the pressure at the membrane outer interface of the primary plasma separator by monitoring the pressure of the gas. The second pressure monitoring element is connected via a second pressure monitoring tube to the pipeline between the membrane outer interface of the secondary plasma component separator and the second flow control element. The second pressure monitoring tube contains gas, and the second pressure monitoring element characterizes the pressure at the membrane outer interface of the secondary plasma component separator by monitoring the pressure of the gas.
[0014] In an exemplary embodiment, the preset primary membrane backflushing parameters of the control unit include backflushing flow rate, backflushing duration, and minimum backflushing interval time, and the preset secondary membrane backflushing parameters include backflushing flow rate, backflushing duration, and minimum backflushing interval time, wherein the backflushing flow rate in the secondary membrane backflushing parameters is less than the backflushing flow rate in the primary membrane backflushing parameters, and the backflushing duration in the secondary membrane backflushing parameters is greater than the backflushing duration in the primary membrane backflushing parameters.
[0015] The present invention also provides a dual plasma filtration system, comprising: A blood pump is used to transport blood in the human body; A primary plasma separator, connected to the blood pump, is used to separate blood into blood cell components and plasma components. The primary plasma separator is provided with a first backflow inlet, which is the membrane external interface of the primary plasma separator. A secondary plasma component separator is connected to the plasma outlet of the primary plasma separator and is used to separate the plasma components into low molecular weight components and high molecular weight components. The secondary plasma component separator is provided with a second backflushing inlet, which is the membrane external interface of the secondary plasma component separator. And the online grading backflushing system according to any one of claims 1 to 4, wherein the first backflushing branch of the online grading backflushing system is connected to the backflushing liquid source and the first backflushing inlet, and the second backflushing branch is connected to the backflushing liquid source and the second backflushing inlet.
[0016] In an exemplary embodiment, the primary plasma separator further includes a blood inlet, a blood outlet, and a plasma outlet. The blood inlet is connected to the blood pump, the blood outlet is used to output the blood cell components, and the plasma outlet is connected to the plasma inlet of the secondary plasma component separator.
[0017] In one exemplary embodiment, a thrombus / protein deposition filter is further included, disposed between the blood outlet of the primary plasma separator and the human body reinfusion pathway, for intercepting protein clots and microthrombi carried in the backflushing waste liquid flowing out from the blood side of the primary plasma separator.
[0018] In an exemplary embodiment, the secondary plasma component separator further includes a plasma inlet, a reflux plasma outlet, and a waste liquid outlet. The plasma inlet is connected to the plasma outlet of the primary plasma separator. The reflux plasma outlet is used to reinfuse the low molecular weight components back into the human body. The waste liquid outlet is used to discharge the retained high molecular weight components. The dual plasma filtration system also includes a waste liquid collection branch connected to the waste liquid outlet for collecting backflushing waste liquid. The backflushing waste liquid carries detached protein clots and microthrombi and is discharged independently without being reinfused into the patient.
[0019] The present invention also provides a control method for an online graded backflush system, applied to the above-mentioned online graded backflush system, comprising the following steps: S1: The control unit presets a primary membrane backflush trigger threshold and a secondary membrane backflush trigger threshold; S2: During treatment, the first pressure monitoring device monitors the transmembrane pressure of the primary plasma separator in real time, and the second pressure monitoring device monitors the transmembrane pressure of the secondary plasma component separator in real time; S3: When the transmembrane pressure of the primary plasma separator reaches the primary membrane backflush trigger threshold, the control unit triggers the primary membrane backflush program, controlling the backflush fluid to flush the inner wall of the primary plasma separator from the outside of the membrane in the opposite direction. S4: When the transmembrane pressure of the secondary plasma component separator reaches the secondary membrane backflush trigger threshold, the control unit triggers the secondary membrane backflush program, controlling the backflush fluid to flush the inner wall of the membrane from the outside of the membrane of the secondary plasma component separator in the opposite direction. The primary membrane backflushing procedure and the secondary membrane backflushing procedure are independent of each other and can be executed in separate time slots.
[0020] In an exemplary embodiment, in step S3, the triggering condition for the primary membrane backflushing procedure further includes a time interval between the last primary membrane backflushing and a preset minimum primary membrane backflushing interval; in step S4, the triggering condition for the secondary membrane backflushing procedure further includes a time interval between the last secondary membrane backflushing and a preset minimum secondary membrane backflushing interval.
[0021] The present invention achieves the following technical effects compared to the prior art: 1. Achieving independent reverse transmembrane flushing of DFPP dual-stage membranes for the first time, significantly improving unclogging performance: By setting a first backflushing inlet on the primary plasma separator and a second backflushing inlet on the secondary plasma component separator, and connecting them to the backflushing fluid source through first and second backflushing branches respectively, the backflushing fluid penetrates the hollow fiber membrane wall from the outer interfaces of both stages into the blood / plasma side. The resulting reverse transmembrane pressure physically peels away the protein cake layer and lipid deposits firmly attached to the inner membrane wall. Compared to the forward flushing of existing technologies, which can only flush away free impurities, reverse transmembrane flushing significantly improves unclogging performance and can directly restore membrane permeability.
[0022] 2. A hierarchical, independent control structure enables differentiated and precise maintenance: The first and second backflush branches are independently configured, with their respective flow control elements controlling the on / off state and flow rate. Combined with first and second pressure monitoring elements that monitor the transmembrane pressure of the primary and secondary membranes respectively, the control unit can independently trigger the primary and secondary membrane backflushes based on the actual blockage status of each membrane. This hierarchical, independent design solves the technical problem of existing technologies where two membranes share the same flushing path, making differentiated maintenance impossible. It allows the primary membrane to focus on flushing the blood cell adhesion layer, while the secondary membrane can focus on removing the dense protein layer, avoiding wasteful or insufficient flushing with a "one-size-fits-all" approach.
[0023] 3. Real-time monitoring combined with automatic control enables precise backflushing on demand: The first pressure monitoring element monitors the transmembrane pressure of the primary plasma separator in real time, and the second pressure monitoring element monitors the transmembrane pressure of the secondary plasma component separator in real time. The control unit automatically determines whether and when to trigger backflushing based on the monitored values, changing the passive situation of existing technologies that rely on manual experience to judge the flushing timing. Based on the automatic triggering mechanism of real-time transmembrane pressure data, backflushing can be initiated immediately when membrane blockage reaches a preset threshold, accurately grasping the maintenance timing and avoiding premature flushing that wastes backflushing fluid or premature flushing that leads to irreversible filter failure.
[0024] 4. The membrane external interface serves as the backflushing inlet, resulting in a simple and reliable structure: By defining the first and second backflushing inlets as the membrane external interfaces of their respective separators, the inherent membrane external (dialysis fluid side / waste fluid side) interface structure of the plasma separator is fully utilized. No structural modifications to the separator body are required, and the reverse cross-membrane flushing function can be achieved simply through external pipeline connection. The structure is simple, the modification cost is low, and it is easy to promote and implement on existing DFPP equipment.
[0025] 5. Significantly reduced volume interference and improved treatment safety: Due to the use of reverse transmembrane flushing from the outside of the membrane, only 50-100 mL of backflushing fluid is needed to effectively remove deposits, far lower than the 150-300 mL required for traditional forward flushing. Combined with precise control of the backflushing fluid volume by the control unit, it has minimal impact on the patient's circulatory volume, making it particularly suitable for volume-sensitive patients such as those with heart failure, liver failure, or shock.
[0026] 6. Reduced consumable costs: Through online graded backflushing, the service life of a single set of dual-stage filters is extended, and there is no need to replace the entire set of consumables during a single treatment. The cost of consumables for DFPP treatment can be significantly reduced, alleviating the economic burden on patients. Attached Figure Description
[0027] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0028] Figure 1 This is a schematic diagram of existing technology; Figure 2 A schematic diagram of a dual plasma filtration system including an online graded backflushing system, as disclosed in a specific embodiment of the present invention; Figure 3 for Figure 2 Schematic diagram of the intermediate-stage plasma separator; Figure 4 for Figure 2 Schematic diagram of the secondary plasma separator; The components include: 1. Blood pump; 2. Primary plasma separator; 201. Blood inlet; 202. Plasma outlet; 203. First backflushing inlet; 204. Blood outlet; 3. Thrombus / protein deposition filter; 4. Replacement fluid pump; 5. Replacement fluid; 6. Plasma separation pump; 7. Secondary plasma component separator; 701. Plasma inlet; 702. Return plasma outlet; 703. Second backflushing inlet; 704. Waste outlet; 8. Waste pump; 9. Waste collection device; 10. First backflushing branch; 11. First pressure monitoring tube; 12. First flow control element; 13. First pressure monitoring element; 14. Second backflushing branch; 15. Second pressure monitoring tube; 16. Second flow control element; 17. Second pressure monitoring element; 18. Flushing fluid pump; 19. Backflushing fluid source; 20. Control unit. Detailed Implementation
[0029] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0030] The purpose of this invention is to provide an online graded backflushing system and its control method, as well as a dual plasma filtration system including the same, to solve the problems existing in the prior art, so that reverse transmembrane flushing can be independently triggered according to the real-time status of the two membranes during treatment, effectively delaying membrane clogging, extending filter life and reducing consumable costs.
[0031] It should be noted first that the online graded backflushing system and its control method claimed in this invention directly target the primary plasma separator and the secondary plasma component separator in a dual plasma filtration device, and belong to the flushing control scheme for filter components in extracorporeal circulation pipelines. The backflushing fluid penetrates the hollow fiber membrane wall from the outside of the membrane and is discharged from the inside of the membrane through the waste liquid outlet or blood outlet. The entire backflushing process does not directly contact the patient's internal tissues or organs. The technical problem to be solved by this invention is filter blockage caused by protein deposition on the membrane surface. Its direct technical effect is to remove adhesions from the inner wall of the membrane, restore membrane permeability, and extend the service life of the filter. It is a maintenance and performance restoration of the filter itself, not a diagnosis or treatment of the disease itself. This invention does not involve purification steps for patient body fluids, nor does it involve adjustment or control of treatment parameters (such as replacement fluid volume, waste liquid disposal volume, anticoagulant dosage, etc.). Therefore, it does not fall under the category of diagnosis and treatment methods for diseases as stipulated in Article 25, Paragraph 1, Item (3) of the Patent Law.
[0032] To make the above-mentioned objects, features and advantages of the present invention more readily understood, the present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.
[0033] Example 1: Online graded backflush system like Figure 2 As shown, this embodiment provides an online graded backflushing system. This backflushing system can be used as an independent functional module in conjunction with existing dual plasma filtration (DFPP) devices to achieve independent reverse transmembrane flushing of the primary plasma separator and the secondary plasma component separator during treatment.
[0034] The online graded backflushing system mainly includes: a backflushing liquid source 19, a first backflushing branch 10, a second backflushing branch 14, a first pressure monitoring element 13, a second pressure monitoring element 17, and a control unit 20.
[0035] The backflush source 19 is used to store and provide backflush fluid. In a preferred embodiment of the invention, the backflush fluid is sterile saline solution, which can be sourced from saline bags or bottles suspended on the infusion stand of the device, or from a storage container built into the device. A flushing fluid pump 18 is installed between the backflush source 19 and each backflush branch, providing the driving force for the flow of backflush fluid in the pipeline. The flushing fluid pump 18 is preferably a peristaltic pump, which achieves liquid delivery by periodically squeezing the pump tube with rollers. It has advantages such as high delivery accuracy, only the pump tube being in contact with the liquid, and ease of replacement and disinfection. The rotational speed of the peristaltic pump is detected by an optocoupler sensor, and a fixed volume of liquid is output per revolution. Therefore, the flow rate of the backflush fluid can be precisely controlled by adjusting the rotational speed. The flushing fluid pump 18 is electrically connected to the control unit 20, which controls its start / stop and rotational speed.
[0036] The first backflush branch 10 connects the backflush fluid source 19 to the membrane interface of the primary plasma separator 2. Specifically, the inlet end of the first backflush branch 10 is connected to the output end of the flushing fluid pump 18 via a pipeline, and the outlet end is connected to the first backflush inlet 203 of the primary plasma separator 2. A first flow control element 12 is provided on the first backflush branch 10, which is used to control the on / off state of the first backflush branch 10 and the flow rate of the backflush fluid flowing through the branch. As a preferred embodiment of the present invention, the first flow control element 12 is a reversing valve or an electrically controlled on / off valve, which is electrically connected to the control unit 20 and receives instructions from the control unit 20 to perform opening, closing, or opening degree adjustment actions.
[0037] The second backflush branch 14 connects the backflush fluid source 19 to the membrane interface of the secondary plasma component separator 7. Specifically, the inlet end of the second backflush branch 14 is connected to the output end of the flushing fluid pump 18 via a pipeline (i.e., the first backflush branch 10 and the second backflush branch 14 share the same flushing fluid pump 18), and the outlet end is connected to the second backflush inlet 703 of the secondary plasma component separator 7. A second flow control element 16 is provided on the second backflush branch 14, which is used to control the on / off state of the second backflush branch 14 and the flow rate of the backflush fluid flowing through the branch. The second flow control element 16 is preferably a reversing valve or an electrically controlled on / off valve, and is electrically connected to the control unit 20. The first backflush branch 10 and the second backflush branch 14 are arranged in parallel downstream of the flushing fluid pump 18 and are each independently controlled.
[0038] As an alternative implementation, the first backflush branch 10 and the second backflush branch 14 can also be equipped with separate flushing fluid pumps, that is, each backflush branch is equipped with its own backflush fluid pump to achieve more independent flow control. In this implementation, both backflush fluid pumps are electrically connected to the control unit 20 and are independently controlled by the control unit 20.
[0039] The first pressure monitoring element 13 is used to monitor the pressure outside the membrane of the primary plasma separator 2. For example... Figure 2As shown, the first pressure monitoring element 13 is connected to the pipeline between the first backflushing inlet 203 and the first flow control element 12 of the primary plasma separator 2 via the first pressure monitoring tube 11. The first pressure monitoring tube 11 contains a certain amount of gas under normal treatment conditions (i.e., without backflushing). During normal operation of the primary plasma separator 2, the blood pump 1 continuously pumps human blood into the blood inlet 201 of the primary plasma separator 2, and the blood flows along the inner cavity of the hollow fiber membrane. The plasma separation pump 6 is located downstream of the plasma outlet 202 of the primary plasma separator 2. When it operates, it generates a negative pressure suction force on the outside of the membrane, creating a pressure difference across the membrane. Driven by this pressure difference, some plasma permeates through the hollow fiber membrane wall into the space outside the membrane and flows out through the plasma outlet 202. Blood cells that fail to permeate the membrane wall and the remaining plasma components continue to flow out along the inner cavity from the blood outlet 204.
[0040] As treatment time increases, large molecules such as lipoproteins, immunoglobulins, and fibrinogen in the plasma gradually adsorb onto the inner wall of the membrane, forming a dense protein deposit layer, leading to a decrease in membrane permeability. Decreased membrane permeability means a reduction in the amount of plasma that can permeate the membrane per unit time. With the plasma pump 6 maintaining a constant suction rate, the reduced amount of plasma entering the membrane results in a corresponding decrease in the amount of liquid flowing through the first backflushing inlet 203 into the pipeline between the first backflushing inlet 203 and the first flow control element 12, as well as into the first pressure monitoring tube 11. Since this liquid compresses the gas in the first pressure monitoring tube 11, the reduced liquid volume means a lower degree of gas compression, thus lowering the gas pressure within the first pressure monitoring tube 11. The first pressure monitoring element 13 can reflect the pressure state outside the membrane of the primary plasma separator 2 by monitoring this gas pressure, thereby indirectly reflecting the membrane's permeability performance—the more severe the protein deposition on the membrane surface, the lower the monitored gas pressure.
[0041] In other words, in the pressure monitoring scheme of this invention, the monitored gas pressure change is negatively correlated with the degree of membrane blockage—the more severe the membrane blockage, the less plasma permeates through the membrane, the less liquid enters the pressure monitoring tube, the lower the degree of gas compression, and the lower the gas pressure. This monitoring principle differs from the conventional method of directly monitoring the liquid pressure on both sides of the membrane, and has advantages such as eliminating the need for a pressure sensor on the blood side, a simpler structure, and avoiding direct contact between blood and the sensor.
[0042] The first pressure monitoring element 13 collects the pressure value of the gas inside the first pressure monitoring tube 11 in real time and converts it into an electrical signal, which is then uploaded to the control unit 20. Based on this signal, the control unit 20 can determine the real-time pressure status outside the membrane of the primary plasma separator 2.
[0043] The structure and principle of the second pressure monitoring device 17 are similar to those of the first pressure monitoring device 13. The second pressure monitoring device 17 is connected to the pipeline between the second backflushing inlet 703 and the second flow control device 16 of the secondary plasma component separator 7 via the second pressure monitoring tube 15. The second pressure monitoring tube 15 also contains gas under normal treatment conditions. During operation, plasma from the primary plasma separator 2 enters the hollow fiber membrane cavity through the plasma inlet 701. The plasma pump 6 is located upstream of the secondary plasma component separator 7 and continuously pushes plasma into the cavity of the secondary plasma component separator 7, creating a pressure difference across the membrane. Small molecule components (such as albumin) are driven by this pressure difference to pass through the membrane wall and enter the outer side of the membrane, and are returned to the human body through the reflux plasma outlet 702; large molecule pathogenic substances (such as immune complexes, low-density lipoprotein, IgM, fibrinogen, etc.) are trapped on the inner side of the membrane cavity. As deposits accumulate on the inner wall of the membrane, membrane permeability decreases, reducing the amount of liquid that can permeate through the membrane wall to the outside of the membrane. Consequently, the amount of liquid entering the pipeline between the second backflushing inlet 703 and the second flow control element 16, as well as the second pressure monitoring tube 15, decreases. This reduces the degree of gas compression within the second pressure monitoring tube 15, resulting in a lower gas pressure. The second pressure monitoring element 17 monitors this gas pressure to characterize the pressure state outside the membrane of the secondary plasma component separator 7 and uploads the monitoring signal to the control unit 20.
[0044] Both the first pressure monitoring element 13 and the second pressure monitoring element 17 can be pressure detection elements known in the art, such as piezoelectric pressure sensors, strain gauge pressure sensors, or ceramic capacitive pressure sensors. Using an indirect gas pressure measurement method avoids direct contact between the pressure monitoring elements and blood or plasma, reducing the risk of infection and simplifying the disinfection and replacement process of the sensors.
[0045] The control unit 20 is the core control component of the entire online graded backflushing system. The control unit 20 is electrically connected to the first flow controller 12, the second flow controller 16, the first pressure monitoring device 13, the second pressure monitoring device 17, and the flushing fluid pump 18 (the electrical connection can be wired or wireless). The control unit 20 can be in the form of an embedded controller, a programmable logic controller (PLC), a microcontroller, or an application-specific integrated circuit (ASIC), and internally integrates a central processing unit (CPU), memory, input / output interfaces, and necessary drive circuits.
[0046] The control unit 20 incorporates a tiered backflush control algorithm. Before treatment begins, the operator can preset various backflush parameters via a human-machine interface (such as a touchscreen display) connected to the control unit 20. Specifically, the control unit 20 presets a primary membrane backflush trigger threshold P1_th and a secondary membrane backflush trigger threshold P2_th. These thresholds can be adjusted according to clinical needs, for example, they can be set to 0.5 times the initial pressure monitoring value (i.e., backflush is triggered when the monitored gas pressure drops to 50% of the initial value). Simultaneously, the control unit 20 presets primary and secondary membrane backflush parameters. The primary membrane backflush parameters include the primary membrane backflush flow rate Q1, the primary membrane backflush duration t1, and the primary membrane minimum backflush interval time T1_min; the secondary membrane backflush parameters include the secondary membrane backflush flow rate Q2, the secondary membrane backflush duration t2, and the secondary membrane minimum backflush interval time T2_min. Considering that the membrane pore size of the primary plasma separator 2 (typically 0.2~0.5μm) is much larger than that of the secondary plasma component separator 7 (typically 0.01~0.04μm), and their clogging mechanisms differ—the primary membrane mainly faces the adhesion of blood cells, while the secondary membrane faces the dense deposition of lipoproteins and immune complexes—the backflush parameters of the two membranes need to be set differently. In a preferred embodiment of the present invention, the backflush flow rate Q2 of the secondary membrane is less than that of the primary membrane Q1 (Q2 < Q1) to avoid damage to the secondary membrane with excessive backflush flow rate; the backflush duration t2 of the secondary membrane is greater than that of the primary membrane t1 (t2 > t1) to allow for more thorough flushing, addressing the more severe clogging of the secondary membrane.
[0047] During treatment, the control unit 20 receives pressure signals uploaded by the first pressure monitoring device 13 and the second pressure monitoring device 17 in real time, which are denoted as P1 and P2, respectively. The control unit 20 compares the ratio of P1 to the initial value (or the average value of the previous 15 minutes) with a preset primary membrane backflushing trigger threshold P1_th, and simultaneously compares the ratio of P2 to the initial value (or the average value of the previous 15 minutes) with a preset secondary membrane backflushing trigger threshold P2_th. When the ratio of P1 to the initial value is less than or equal to P1_th and the time since the last primary membrane backflushing is greater than or equal to T1_min, the control unit 20 triggers the primary membrane backflushing procedure; when the ratio of P2 to the initial value is less than or equal to P2_th and the time since the last secondary membrane backflushing is greater than or equal to T2_min, the control unit 20 triggers the secondary membrane backflushing procedure. The primary and secondary membrane backflushing procedures are independent of each other, can be executed in time-sharing, and do not interfere with each other.
[0048] Taking the primary membrane backflushing procedure as an example, when the backflushing conditions are met, the control unit 20 first sends a command to the pump (such as the plasma separation pump 6) associated with the plasma treatment pathway of the primary plasma separator 2, causing it to stop operating (i.e., the speed drops to zero), thereby closing the normal plasma treatment pathway of this stage of the membrane. Subsequently, the control unit 20 controls the first flow control element 12 to open the first backflushing branch 10, and simultaneously starts the flushing fluid pump 18 (if the flushing fluid pump 18 is already running, it will continue to run). Driven by the flushing fluid pump 18, the backflushing fluid (sterile saline) enters the outer side of the membrane of the primary plasma separator 2 (i.e., the outer space of the hollow fiber membrane) through the first backflushing branch 10 and the first backflushing inlet 203. Since the pressure on the inner side of the membrane (blood side) is lower than the backflushing fluid pressure on the outer side of the membrane at this time, the backflushing fluid penetrates the membrane wall of the hollow fiber membrane in reverse under the action of the reverse pressure difference, flowing from the outer side of the membrane to the inner side of the membrane (i.e., the inner lumen of the blood side). The shear force generated by this reverse flow can effectively peel off the protein deposits and lipid plaques that have been firmly adhered to the inner wall of the membrane. The detached deposits flow out of the membrane cavity through the blood outlet 204 along with the backflushing fluid. After the preset backflushing time t1 is reached, the control unit 20 controls the first flow control element 12 to close the first backflushing branch 10, stops backflushing, and sends a command to the plasma pump 6 to restore its normal speed, so that the system returns to normal treatment status.
[0049] The working principle of the secondary membrane backflushing procedure is similar to that of the primary membrane, but the flow direction of the backflushing waste liquid is different. When the secondary membrane backflushing conditions are met, the control unit 20 controls the plasma pump 6 to stop operating to close the normal plasma treatment pathway of the secondary membrane. Subsequently, the second flow control element 16 is controlled to open the second backflushing branch 14. The backflushing fluid enters the outer side of the membrane of the secondary plasma component separator 7 through the second backflushing branch 14 and the second backflushing inlet 703. After penetrating the membrane wall in reverse, it is discharged from the inner side of the membrane through the waste liquid outlet 704, carrying the detached protein clots and microthrombi into the waste liquid collection device 9, and is not reinfused into the patient.
[0050] The aforementioned online grading backflushing system, as an independent functional module, can be easily integrated with existing DFPP equipment. Existing DFPP equipment only needs to connect the backflushing branch of this system to the membrane external interface of the two-stage separator, and connect the control unit to the original pump and valve control interfaces of the equipment to achieve upgrades without requiring large-scale structural modifications to the equipment itself.
[0051] The online graded backflushing system described in this embodiment, by setting independent backflushing branches and flow control components for the two-stage separators, combined with pressure monitoring components that monitor the pressure outside the two-stage membranes (indirectly achieved by monitoring the gas pressure inside the pressure monitoring tube) and a centralized control unit, has for the first time realized reverse cross-membrane flushing of the two-stage filters independently based on real-time monitoring of the pressure outside the membrane in the DFPP field. This effectively solves the technical problems in the prior art where the two-stage membranes share the same flushing path, cannot be maintained differently, cannot be reverse flushed, and cannot be precisely triggered as needed.
[0052] Example 2: Dual Plasma Filtration System This embodiment provides a dual plasma filtration system that integrates the online graded backflushing system described in Embodiment 1, forming a complete DFPP treatment device.
[0053] like Figure 2 As shown, the dual plasma filtration system mainly includes: a blood pump 1, a primary plasma separator 2, a secondary plasma component separator 7, a replacement fluid pump 4, a plasma separation pump 6, a waste liquid pump 8, a waste liquid collection device 9, and the online grading backflushing system described in Example 1.
[0054] Blood pump 1 is the driving force for the entire extracorporeal circulation system, used to draw blood from the patient and deliver it into the extracorporeal circulation tubing. The inlet of blood pump 1 is connected to the patient's arterial vascular access (such as a central venous catheter or peripheral arterial puncture needle) via tubing, and the outlet is connected to the blood inlet 201 of the primary plasma separator 2 via tubing. Blood pump 1 is preferably a peristaltic pump, which can precisely control the blood flow rate by adjusting its rotation speed. The adjustable range of blood flow rate is 50~200 mL / min, with the specific value set according to clinical orders. Blood pump 1 is electrically connected to control unit 20, which controls its start / stop and rotation speed.
[0055] The primary plasma separator 2 is the first-stage separation device in the DFPP system, used to separate whole blood into blood cell components and plasma components. For example... Figure 2 and Figure 3 As shown, the primary plasma separator 2 adopts a hollow fiber membrane structure, with a large number of hollow fiber membrane filaments encapsulated inside its shell. The hollow fiber membrane has a relatively large pore size, typically 0.2~0.5μm, allowing plasma and all solutes in it to pass freely, while blood cells (red blood cells, white blood cells, and platelets) are trapped in the membrane lumen.
[0056] The primary plasma separator 2 has four interfaces: a blood inlet 201, a blood outlet 204, a plasma outlet 202, and a first backflushing inlet 203. The blood inlet 201 is located at one end of the separator housing and connects to the outlet end of the blood pump 1, used to receive whole blood from the blood pump 1. Blood enters the inner cavity of the hollow fiber membrane through the blood inlet 201 and flows along the inner cavity to the other end. During the flow, the plasma pump 6 continuously draws suction downstream of the plasma outlet 202, generating negative pressure and creating a pressure difference across the membrane. Driven by this pressure difference, plasma components permeate through the membrane wall of the hollow fiber membrane into the space outside the membrane (i.e., the space between the inner cavity of the housing and the outer wall of the fiber membrane), and flow out through the plasma outlet 202 located on the side wall of the housing. Blood cells that fail to permeate the membrane wall and a small amount of residual plasma continue to flow along the inner cavity of the fiber membrane, eventually flowing out from the blood outlet 204 located at the other end of the housing. The blood outlet 204 is connected to the human body reinfusion pathway (i.e., the venous end vascular pathway) through the tubing and thrombus / protein deposition filter 3, so as to reinfuse blood cell components back into the patient's body.
[0057] The first backflush inlet 203 is located on the side wall of the housing of the primary plasma separator 2 and communicates with the space outside the membrane; that is, the first backflush inlet 203 is the membrane external interface of the separator. The first backflush inlet 203 is used to connect backflush fluid in backflush mode. In normal treatment mode, the first backflush inlet 203 is closed or in a non-use state.
[0058] The secondary plasma component separator 7 is the second-stage separation device in the DFPP system, used to further separate the plasma obtained from the primary separation into low-molecular-weight components and high-molecular-weight components. For example... Figure 2 and Figure 4 As shown, the secondary plasma component separator 7 also adopts a hollow fiber membrane structure, but its membrane pore size is much smaller than that of the primary plasma separator 2, usually 0.01~0.04μm. It only allows small molecules such as albumin to pass through, while retaining large pathogenic molecules such as immunoglobulins, low-density lipoproteins, and fibrinogen.
[0059] The secondary plasma component separator 7 has four interfaces: a plasma inlet 701, a reflux plasma outlet 702, a waste liquid outlet 704, and a second backflushing inlet 703. The plasma inlet 701 is located at one end of the separator housing and is connected to the plasma outlet 202 of the primary plasma separator 2 via a pipeline, used to receive plasma components from the primary plasma separator 2. Plasma enters the inner cavity of the hollow fiber membrane through the plasma inlet 701 and flows along the inner cavity to the other end. During the flow, the plasma pump 6 is located upstream of the secondary plasma component separator 7, continuously supplying plasma into the secondary plasma component separator 7, creating a pressure difference across the membrane. Small molecule components (mainly albumin and substances with even smaller molecular weights) are driven by this pressure difference to permeate through the membrane wall into the outer space of the membrane and flow out through the reflux plasma outlet 702 located on the side wall of the housing. The reflux plasma outlet 702 is connected to the human body reinfusion pathway via a pipeline (usually connected to the pipeline downstream of the blood outlet 204 of the primary plasma separator 2), returning the purified plasma components and blood cell components to the patient. The large molecular pathogens trapped in the membrane lumen continue to slowly advance along the lumen toward the waste liquid outlet 704.
[0060] Waste liquid outlet 704 is located at the other end of the separator housing and is connected to waste liquid collection device 9 via pipeline and waste liquid pump 8. Waste liquid pump 8 is used to control the discharge of waste liquid. During treatment, the plasma pump 6 continuously delivers plasma into the secondary plasma component separator 7. Since the waste liquid pump 8 is not continuously running at full speed, its operating speed is lower than the delivery rate of the plasma pump 6. As a result, most of the plasma in the inner cavity of the secondary plasma component separator 7 is discharged from the reflux plasma outlet 702 and returned to the human body along with the small molecules that have passed through the membrane wall under the continuous push of the plasma pump 6. Only when the large molecules trapped in the inner cavity accumulate to a certain amount will the waste liquid pump 8 start to discharge the waste plasma containing large pathogenic molecules to the waste liquid collection device 9. Alternatively, the waste liquid pump 8 can operate continuously at a constant low speed, making its flow rate lower than that of the plasma pump 6. In this case, most of the plasma in the inner cavity of the secondary plasma component separator 7 is returned to the human body from the reflux plasma outlet 702 under the continuous push of the plasma pump 6, and only the portion of plasma that is within the discharge capacity of the waste liquid pump 8 and the large molecules trapped in it are discharged from the waste liquid outlet 704. In other words, the waste fluid pump 8 does not actively aspirate the fluid inside the membrane during normal treatment. Its function is to control the discharge volume of waste fluid, ensuring that the inner cavity of the secondary plasma component separator 7 always maintains a certain amount of plasma filling and flow, thus maintaining normal substance exchange. The waste fluid pump 8 can be a peristaltic pump, electrically connected to the control unit 20, which controls its start-up, shutdown, and speed.
[0061] The second backflush inlet 703 is located on the side wall of the housing of the secondary plasma component separator 7 and communicates with the space outside the membrane; that is, the second backflush inlet 703 is the membrane external interface of the separator. The second backflush inlet 703 is used to introduce backflush fluid in backflush mode. In normal treatment mode, the second backflush inlet 703 is closed or in a non-use state.
[0062] Replacement fluid 5 is fresh frozen plasma, intended to replenish plasma components lost during treatment and prevent shock caused by colloid osmotic pressure imbalance. Replacement fluid 5 is stored in a replacement fluid bag and connected to the body's reinfusion pathway via tubing and replacement fluid pump 4. Replacement fluid pump 4 is electrically connected to control unit 20, which controls its delivery rate, allowing replacement fluid 5 to enter the blood circuit at a set rate as prescribed by the doctor.
[0063] Plasma pump 6 is installed in the pipeline between the plasma outlet 202 of the primary plasma separator 2 and the plasma inlet 701 of the secondary plasma component separator 7, and is used to transport the plasma separated by the primary plasma separator 2 to the secondary plasma component separator 7. Plasma pump 6 is preferably a peristaltic pump, electrically connected to control unit 20, which controls its start / stop and rotation speed. In normal treatment mode, plasma pump 6 operates at a set speed to maintain a stable flow of plasma between the two separators. The operation of plasma pump 6 generates negative pressure outside the membrane, providing driving force for plasma to pass through the membrane walls of the two separators. In backflushing mode, control unit 20 controls plasma pump 6 to stop operating (rotation speed drops to zero), thereby closing the normal plasma treatment pathway of this stage of the membrane.
[0064] Waste pump 8 is installed on the pipeline between the waste outlet 704 of the secondary plasma component separator 7 and the waste collection device 9. Waste pump 8 controls the discharge of waste liquid from the inner cavity of the secondary plasma component separator 7. In normal treatment mode, the operating speed of waste pump 8 is lower than the delivery rate of plasma pump 6, allowing the inner cavity of the secondary plasma component separator 7 to be filled with plasma. Most of the plasma is returned to the body from the reflux plasma outlet 702 under the continuous push of plasma pump 6. Only when the large molecules trapped in the inner cavity accumulate to a certain extent will waste pump 8 start or increase its speed to discharge waste plasma containing large pathogenic molecules to waste collection device 9. In backflushing mode, control unit 20 can control waste pump 8 to start or maintain operation, transporting backflushing waste liquid generated by secondary membrane backflushing, along with detached protein clots and microthrombi, to waste collection device 9. Waste collection device 9 is a disposable waste bag or waste bucket used to collect waste plasma and backflushing waste liquid generated by secondary membrane backflushing.
[0065] A thrombus / protein deposition filter 3 is installed in the tubing between the blood outlet 204 of the primary plasma separator 2 and the patient's reinfusion pathway. This filter is used to filter out small protein clots and microthrombi that may be carried in the fluid flowing out of the blood outlet 204 of the primary plasma separator 2. In normal treatment mode, the blood outlet 204 of the primary plasma separator 2 contains blood cell components and usually does not contain large clots; however, in backflushing mode, when the backflushing fluid penetrates the membrane wall from the outside of the membrane and enters the blood-side lumen, it peels off the protein deposits adhering to the inner wall of the membrane. These peeled materials flow out of the blood outlet 204 with the backflushing fluid. The function of the thrombus / protein deposition filter 3 is to intercept these peeled materials before they enter the patient's reinfusion pathway, ensuring that the fluid reinfused into the patient is safe and free of embolism risk. The thrombus / protein deposition filter 3 can be a conventional blood filter in the art, with a pore size typically of 40~200μm, which can effectively intercept small clots while allowing blood cells to pass freely.
[0066] The dual plasma filtration system described in this embodiment integrates the online graded backflushing system described in Embodiment 1. Specifically, the first backflushing branch 10 of the online graded backflushing system connects the backflushing fluid source 19 to the first backflushing inlet 203 of the primary plasma separator 2; the second backflushing branch 14 connects the backflushing fluid source 19 to the second backflushing inlet 703 of the secondary plasma component separator 7. The control unit 20 simultaneously controls the blood pump 1, replacement fluid pump 4, plasma separation pump 6, waste fluid pump 8, and various flow control components, pressure monitoring components, and flushing fluid pump 18 of the online graded backflushing system, realizing automated control of the entire DFPP treatment process and independent triggering and execution of the online graded backflushing.
[0067] The dual plasma filtration system described in this embodiment integrates an online graded backflushing function on the basis of a complete DFPP treatment device. It can independently trigger backflushing based on the real-time external pressure status of each of the two membrane stages without interrupting treatment, effectively extending the filter's service life, reducing the frequency of treatment interruptions, lowering consumable costs, and minimizing interference with the patient's circulatory volume.
[0068] Example 3: Control Method of Online Staged Backflush System This embodiment provides a control method for an online graded backflushing system, which can be applied to the online graded backflushing system described in Embodiment 1 or the dual plasma filtration system described in Embodiment 2.
[0069] Step S1: Parameter preset Before treatment begins, the operator presets various backflush parameters in the control unit 20 via the human-machine interface. Specifically, this includes presetting the primary membrane backflush trigger threshold P1_th and the secondary membrane backflush trigger threshold P2_th. In a preferred embodiment of the invention, P1_th and P2_th can each be set to 0.5, meaning that backflush is triggered when the monitored gas pressure drops to 50% of the initial value (or the average value over the previous 15 minutes). (This ratio can be adjusted by the clinician based on the patient's specific condition, for example, it can be set to any value within the range of 0.4 to 0.6.) Simultaneously, primary membrane backflush parameters (primary membrane backflush flow rate Q1, primary membrane backflush duration t1, and primary membrane minimum backflush interval T1_min) and secondary membrane backflush parameters (secondary membrane backflush flow rate Q2, secondary membrane backflush duration t2, and secondary membrane minimum backflush interval T2_min) are preset. In a preferred embodiment of the invention, Q2 < Q1 and t2 > t1 are set to accommodate the smaller pore size and more severe blockage of the secondary membrane. The typical range of values for the above parameters is as follows: Q1 is 80~120mL / min, Q2 is 50~80mL / min; t1 is 30~60 seconds, t2 is 60~120 seconds; T1_min and T2_min are both 5~15 minutes (the specific values are set according to clinical needs).
[0070] Step S2: Real-time monitoring During treatment, the first pressure monitoring device 13 monitors the gas pressure P1 in the first pressure monitoring tube 11 in real time, and the second pressure monitoring device 17 monitors the gas pressure P2 in the second pressure monitoring tube 15 in real time. The monitoring signals are uploaded to the control unit 20 in real time. The control unit 20 performs analog-to-digital conversion and data processing on the received signals, calculates the real-time values of P1 and P2, and compares them with the preset initial values (or the average value of the previous 15 minutes) to calculate the current pressure ratios R1=P1 / P1_initial and R2=P2 / P2_initial.
[0071] Step S3: Independent Trigger Judgment Control unit 20 performs independent triggering judgments for the two membrane stages respectively: For the primary membrane, the control unit 20 determines whether the current pressure ratio R1 is less than or equal to the preset primary membrane backflush trigger threshold P1_th (e.g., 0.5), and at the same time determines whether the time since the last primary membrane backflush is greater than or equal to the primary membrane minimum backflush interval T1_min. If both conditions are met, the primary membrane backflush procedure is triggered.
[0072] For the secondary membrane, the control unit 20 determines whether the current pressure ratio R2 is less than or equal to the preset secondary membrane backflush trigger threshold P2_th (e.g., 0.5), and at the same time determines whether the time since the last secondary membrane backflush is greater than or equal to the minimum secondary membrane backflush interval T2_min. If both conditions are met, the secondary membrane backflush procedure is triggered.
[0073] The triggering decisions for the two membrane stages are independent and do not affect each other. Therefore, the primary membrane backflush procedure and the secondary membrane backflush procedure can be executed in a time-sharing manner or simultaneously (provided that their respective conditions are met), and there is no temporal dependency between them.
[0074] Step S4: Recoil Execution Taking the first-stage membrane backflushing procedure as an example, its execution process includes the following sub-steps: S4-1: The control unit 20 sends a command to the plasma pump 6 to stop its operation (the speed is reduced to zero), thereby shutting down the normal plasma therapy pathway of the primary plasma separator 2.
[0075] S4-2: Control unit 20 controls the first flow control element 12 to open the first backflow branch 10.
[0076] S4-3: Control unit 20 controls flushing pump 18 to operate at a preset primary membrane backflushing flow rate Q1 (if flushing pump 18 has not yet started). Driven by flushing pump 18, backflushing fluid (sterile saline) enters the outer side of the membrane of primary plasma separator 2 through first backflushing inlet 203 via first backflushing branch 10. Because the pressure of backflushing fluid is higher than the pressure on the inner side of the membrane (blood side), backflushing fluid penetrates the membrane wall of hollow fiber membrane in the reverse direction under the action of reverse pressure difference, flowing from the outer side of the membrane to the inner side. This reverse flow generates shear force on the inner wall of the membrane, physically peeling off the protein deposits and lipid plaques that have firmly adhered to the inner wall of the membrane.
[0077] S4-4: The detached protein clots and microthrombi flow out from the membrane lumen through blood outlet 204 with the backflushing fluid. After the backflushing waste fluid is filtered through thrombus / protein deposition filter 3, the protein clots and microthrombi are intercepted. The filtered fluid (mainly physiological saline and a small amount of plasma components) continues to be reinfused into the patient through the tubing.
[0078] S4-5: After the preset first-stage membrane backflushing time t1 is reached, the control unit 20 controls the flushing fluid pump 18 to stop (or maintain standby state), controls the first flow control element 12 to close the first backflushing branch 10, and at the same time sends a command to the pulp pump 6 to restore its normal speed, so that the system returns to normal treatment state.
[0079] The execution process of the secondary membrane backflushing procedure is similar to that of the primary membrane, but the flow direction and treatment method of the backflushing waste liquid are different: S4-1': Control unit 20 sends a command to plasma pump 6 to stop its operation, thereby shutting down the normal plasma therapy pathway of secondary plasma component separator 7.
[0080] S4-2': Control unit 20 controls the second flow control element 16 to open the second backflow branch 14.
[0081] S4-3': Control unit 20 controls flushing fluid pump 18 to operate at a preset secondary membrane backflushing flow rate Q2. The backflushing fluid enters the outer side of the membrane of the secondary plasma component separator 7 through the second backflushing branch 14 from the second backflushing inlet 703, and then penetrates the hollow fiber membrane wall in reverse to enter the inner side of the membrane (plasma side cavity).
[0082] S4-4': The detached protein clots and microthrombi flow out from the membrane lumen through waste outlet 704 with the backflushing fluid. Control unit 20 controls waste pump 8 to start or maintain operation, transporting backflushing waste fluid through waste collection branch to waste collection device 9 for independent discharge without being reinfused into the patient.
[0083] S4-5': After the preset secondary membrane backflushing time t2 is reached, the control unit 20 controls the flushing fluid pump 18 to stop (or maintain standby state), controls the second flow control element 16 to close the second backflushing branch 14, and at the same time sends a command to the pulp pump 6 to restore its normal speed, so that the system returns to normal treatment state.
[0084] Step S5: Safety Protection During the backflushing process, the control unit 20 continuously monitors various safety indicators. If any of the following abnormalities are detected, the control unit 20 immediately terminates the backflushing and triggers an alarm module: (1) the monitoring value of the first pressure monitoring element 13 or the second pressure monitoring element 17 exceeds the preset safety threshold (indicating a possible risk of membrane rupture); (2) visible hemolysis or blood cell leakage occurs in the waste liquid (indicating a possible membrane rupture). The specific value of the safety threshold is provided by the equipment manufacturer based on the model and specifications of the separator used and is preset in the control unit 20. The alarm module can be an audible and visual alarm or an alarm prompt on the equipment display screen, and can also be used in conjunction with the equipment communication module to send alarm information to medical personnel.
[0085] The control method described in this embodiment achieves precise backflushing of the two-stage filters on demand through an independent triggering mechanism based on real-time external membrane pressure monitoring. This avoids the waste of backflushing fluid and the impact on treatment efficiency caused by premature flushing, as well as the irreversible failure of the filters caused by late flushing. It maximizes the service life of the filters while ensuring the treatment effect.
[0086] In the description of this invention, it should be understood that the terms "longitudinal," "lateral," "center," "axial," "radial," "circumferential," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," and "outer," etc., indicating orientations or positional relationships, are based on the orientations or positional relationships shown in the accompanying drawings and are used only for the convenience of describing the invention, and do not imply or require that the device or element referred to have a specific orientation or construction method, and therefore should not be construed as a limitation of the invention. Furthermore, the terms "first," "second," and "third," etc., are only used to distinguish the objects of description and should not be construed as limiting importance or order, and the features defined by such terms may explicitly or implicitly include one or more of those features. Unless otherwise stated, "a plurality of" in the description of this invention refers to two or more.
[0087] The terms "installation," "connection," and "joining" should be interpreted broadly, unless otherwise explicitly defined, to include, but are not limited to, fixed connections, detachable connections, or integrally formed connections; mechanical or electrical connections; direct connections or indirect connections via an intermediate medium; and internal communication between two components. Those skilled in the art can understand their meaning based on the specific technical solution. The fixed connections involved in this invention, unless otherwise stated, include both detachable fixed connections (such as bolt and screw connections) and non-detachable fixed connections (such as riveting and welding), and may also include integral structures achieved through an integral forming process (such as casting) (except where integral forming is clearly impossible).
[0088] Unless otherwise stated, the terms used in any of the technical solutions disclosed in this invention to indicate positional relationships or shapes cover states or shapes that are similar to, close to, or adjacent to them.
[0089] Any component provided by this invention can be assembled from multiple individual components or can be a single component manufactured using a one-piece molding process.
[0090] It should be noted that the structures, proportions, sizes, etc., depicted in the accompanying drawings of this specification are only for the purpose of assisting those skilled in the art in understanding and reading the content disclosed in the specification, and are not intended to limit the conditions under which the present invention can be implemented. Therefore, they have no substantial technical significance. Any modifications to the structure, changes in the proportions, or adjustments to the size, without affecting the effects and objectives that the present invention can produce, should still fall within the scope of the technical content disclosed in the present invention.
[0091] In the embodiments of this application, the same reference numerals are used to denote the same component or part.
[0092] Any adaptive changes made according to actual needs are within the scope of protection of this invention.
[0093] It should be noted that, for those skilled in the art, it is obvious that the present invention is not limited to the details of the exemplary embodiments described above, and that the invention can be implemented in other specific forms without departing from the spirit or essential characteristics of the invention. Therefore, the embodiments should be considered illustrative and non-limiting in all respects, and the scope of the invention is defined by the appended claims rather than the foregoing description. Thus, all variations falling within the meaning and scope of equivalents of the claims are intended to be included within the present invention. No reference numerals in the claims should be construed as limiting the scope of the claims.
Claims
1. An online grading backflushing system, applied to a dual plasma filtration device, characterized in that, include: Backflush fluid source (19) is used to provide backflush fluid; The first backflush branch (10) is used to connect the backflush liquid source (19) to the membrane outer interface of the primary plasma separator (2), and the first backflush branch (10) is provided with a first flow control element (12). The second backflush branch (14) is used to connect the backflush liquid source (19) to the membrane outer interface of the secondary plasma component separator (7), and a second flow control element (16) is provided on the second backflush branch (14). The first pressure monitoring device (13) is used to monitor the transmembrane pressure of the primary plasma separator (2); The second pressure monitoring device (17) is used to monitor the transmembrane pressure of the secondary plasma component separator (7); The control unit (20) is electrically connected to the first flow control element (12), the second flow control element (16), the first pressure monitoring element (13), and the second pressure monitoring element (17), respectively. The control unit (20) independently controls the on / off state of the first backflushing branch (10) and the second backflushing branch (14) and the backflushing parameters according to the monitoring values of the first pressure monitoring element (13) and the second pressure monitoring element (17), so as to perform independent reverse transmembrane flushing on the primary plasma separator (2) and the secondary plasma component separator (7), respectively.
2. The online graded backflushing system according to claim 1, characterized in that: The control unit (20) has a built-in graded backflush control algorithm. When the monitoring value of the first pressure monitoring device (13) reaches the preset first-stage membrane backflush trigger threshold, the control unit (20) triggers the first-stage membrane backflush program and controls the first flow control device (12) to open the first backflush branch (10). When the monitoring value of the second pressure monitoring device (17) reaches the preset second-stage membrane backflush trigger threshold, the control unit (20) triggers the second-stage membrane backflush program and controls the second flow control device (16) to open the second backflush branch (14). The first-stage membrane backflush program and the second-stage membrane backflush program are independent of each other and can be executed in time.
3. The online graded backflushing system according to claim 1, characterized in that: The first pressure monitoring device (13) is connected to the pipeline between the membrane outer interface of the primary plasma separator (2) and the first flow control device (12) through the first pressure monitoring tube (11). The first pressure monitoring tube (11) contains gas, and the first pressure monitoring device (13) characterizes the pressure at the membrane outer interface of the primary plasma separator (2) by monitoring the pressure of the gas. The second pressure monitoring device (17) is connected to the pipeline between the membrane outer interface of the secondary plasma component separator (7) and the second flow control device (16) through the second pressure monitoring tube (15). The second pressure monitoring tube (15) contains gas, and the second pressure monitoring device (17) characterizes the pressure at the membrane outer interface of the secondary plasma component separator (7) by monitoring the pressure of the gas.
4. The online graded backflushing system according to claim 1, characterized in that: The control unit (20) presets the primary membrane backflushing parameters, including backflushing flow rate, backflushing duration, and minimum backflushing interval time. The preset secondary membrane backflushing parameters include backflushing flow rate, backflushing duration, and minimum backflushing interval time. The backflushing flow rate in the secondary membrane backflushing parameters is less than the backflushing flow rate in the primary membrane backflushing parameters, and the backflushing duration in the secondary membrane backflushing parameters is greater than the backflushing duration in the primary membrane backflushing parameters.
5. A dual plasma filtration system, characterized in that, include: Blood pump (1), used to transport human blood; A primary plasma separator (2) is connected to the blood pump (1) and is used to separate blood into blood cell components and plasma components. The primary plasma separator (2) is provided with a first backflushing inlet (203), which is the membrane outer interface of the primary plasma separator (2). The secondary plasma component separator (7) is connected to the plasma outlet (202) of the primary plasma separator (2) and is used to separate the plasma components into low molecular weight components and high molecular weight components. The secondary plasma component separator (7) is provided with a second backflushing inlet (703), which is the membrane outer interface of the secondary plasma component separator (7). And the online graded backflushing system according to any one of claims 1 to 4, wherein the first backflushing branch (10) of the online graded backflushing system is connected to the backflushing liquid source (19) and the first backflushing inlet (203), and the second backflushing branch (14) is connected to the backflushing liquid source (19) and the second backflushing inlet (703).
6. The dual plasma filtration system according to claim 5, characterized in that: The primary plasma separator (2) is further provided with a blood inlet (201), a blood outlet (204) and a plasma outlet (202). The blood inlet (201) is connected to the blood pump (1), the blood outlet (204) is used to output the blood cell components, and the plasma outlet (202) is connected to the plasma inlet (701) of the secondary plasma component separator (7).
7. The dual plasma filtration system according to claim 6, characterized in that: It also includes a thrombus / protein deposition filter (3), which is set between the blood outlet (204) of the primary plasma separator (2) and the human body reinfusion pathway, to intercept protein clots and microthrombi carried in the backflushing waste liquid flowing out from the blood side of the primary plasma separator (2).
8. The dual plasma filtration system according to claim 5, characterized in that: The secondary plasma component separator (7) is further provided with a plasma inlet (701), a reflux plasma outlet (702), and a waste liquid outlet (704). The plasma inlet (701) is connected to the plasma outlet (202) of the primary plasma separator (2). The reflux plasma outlet (702) is used to reinfuse the low molecular weight components back into the human body. The waste liquid outlet (704) is used to discharge the retained high molecular weight components. The dual plasma filtration system also includes a waste liquid collection branch connected to the waste liquid outlet (704) for collecting backflushing waste liquid. The backflushing waste liquid carries the detached protein clots and microthrombi and is discharged independently without being reinfused into the patient's body.
9. A control method for an online graded backflush system, applied to the online graded backflush system according to any one of claims 1 to 4, characterized in that, Includes the following steps: S1: The control unit (20) presets a primary membrane backflush trigger threshold and a secondary membrane backflush trigger threshold; S2: During the treatment, the first pressure monitoring device (13) monitors the transmembrane pressure of the primary plasma separator (2) in real time, and the second pressure monitoring device (17) monitors the transmembrane pressure of the secondary plasma component separator (7) in real time. S3: When the transmembrane pressure of the primary plasma separator (2) reaches the primary membrane backflush trigger threshold, the control unit (20) triggers the primary membrane backflush procedure and controls the backflush fluid to flush the inner wall of the membrane of the primary plasma separator (2) from the outside of the membrane in the opposite direction. S4: When the transmembrane pressure of the secondary plasma component separator (7) reaches the secondary membrane backflush trigger threshold, the control unit (20) triggers the secondary membrane backflush procedure and controls the backflush fluid to flush the inner wall of the membrane of the secondary plasma component separator (7) from the outside of the membrane in the opposite direction. The primary membrane backflushing procedure and the secondary membrane backflushing procedure are independent of each other and can be executed in separate time slots.
10. The control method for the online graded backflush system according to claim 9, characterized in that: In step S3, the triggering condition for the primary membrane backflushing procedure also includes a time interval between the last primary membrane backflushing and a preset minimum primary membrane backflushing interval. In step S4, the triggering condition for the secondary membrane backflushing procedure also includes a time interval between the last secondary membrane backflushing and a preset minimum secondary membrane backflushing interval.
